Qlucore

Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.

Under the terms of the agreement, Genomax will distribute Qlucore's Omics Explorer software to the Malaysian biotech market.

The company will use the funds to grow its team and to further develop and validate its proprietary deep learning technology.

TATAA Biocenter will use Qlucore's Omics Explorer in its next-generation sequencing courses and client services.

NEW YORK (GenomeWeb) – Qlucore has signed an agreement with Commugene that lets the latter distribute its Qlucore Omics Explorer software to clients in the South Korean biotechnology and pharmaceutical markets.

Swiss bioinformatics firm Nebion and Swedish bioinformatics company Qlucore have agreed to jointly promote their flagship products, thereby offering a complementary set of capabilities for the pharmaceutical and biotechnology industries that can be used for biomarker discovery st

NEW YORK (GenomeWeb News) – Bioinformatics firms Qlucore and Nebion today announced a collaboration to promote each other's data analysis products.

Qlucore has released Omics Explorer 3.0.
This latest version of the company's software includes a new Gene Ontology browser, a Gene Set Enrichment Analysis workbench, and new file import functionality for aligned RNA-seq data.

Qlucore has added three new employees to its staff.

As part of its participation in a European research consortium, Qlucore has been tapped to develop a prototype of a mobile application that will help physicians plan more personalized treatment strategies.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.